We Medical Labs LLC

We Medical Labs LLC was paid $775K by Medicaid between Sep 2020 and Sep 2024, across 31 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 65% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#76 of 436

Median peer was paid$17K

This provider vs. median45×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	1,973	$38K
2021	7,044	$108K
2022	3,908	$75K
2023	1,167	$170K
2024incomplete	2,266	$383K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	65%	2,652	1,304	$505K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	17%	2,980	2,240	$132K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	6.0%	527	231	$47K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	4.7%	2,978	2,243	$37K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	4.5%	2,420	1,797	$35K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	898	863	$7K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	391	315	$3K
80375		<1%	191	185	$1K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	94	93	$899.13
80361		<1%	189	183	$732.99
80348		<1%	189	183	$711.54
80356		<1%	202	195	$699.53

19 more codes

80349		<1%	203	$678.75
80354		<1%	189	$670.36
83992		<1%	202	$635.86
80365		<1%	189	$610.67
80362		<1%	189	$582.81
80353		<1%	207	$568.47
80358		<1%	189	$565.29
80374		<1%	202	$534.71
80373		<1%	189	$529.77
80359		<1%	206	$450.08
80050	General health panel	<1%	26	$232.83
80061	Lipid panel	<1%	84	$124.66
83036	Hemoglobin; glycosylated (A1C)	<1%	89	$105.68
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	28	$103.44
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	90	$68.00
80321		<1%	37	$64.68
80053	Comprehensive metabolic panel	<1%	31	$32.27
84439		<1%	12	$15.76
36415	Collection of venous blood by venipuncture	0%	285	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialAGUILA, EDUARDO (OWNER)